Summary Allelic losses on chromosome 16q in tumour cells are frequent in a variety of malignancies, suggesting the presence of one or more tumour-suppressor genes in the region. Among 210 sporadic breast cancers we examined using 15 microsatellite markers on the long arm of chromosome 16, heterozygosity for at least one locus was lost in 141 (67%). Detailed deletion mapping revealed two distinct commonly deleted regions. One region was defined as a 3-cM interval flanked by markers D16S512 and D16S515 at 16q22; the second consisted of a 9.5-cM interval flanked by markers D16S498 and D16S303 at q24.3. Allelic loss on 16q was observed frequently in small tumours, tumours without lymph node metastasis and tumours of the non-invasive histological type as well as in tumours of more advanced phenotype, suggesting that inactivation of one of at least two tumour-suppressor genes on 16q plays a role in early stage breast carcinogenesis.
INTRODUCTION
Human carcinomas are now considered to develop through the accumulation of genetic changes within a cell lineage. Several genetic alterations that activate oncogenes (c-myc, erbB-2, int2) and/or inactivate known tumour-suppressor genes (p53, Rb) have been documented in breast cancers. Frequent observations of loss of heterozygosity (LOH) at specific chromosomal loci in human tumours are generally understood to signal the presence of tumour-suppressor genes in the affected chromosomal regions. We have demonstrated frequent LOH on chromosomes 3p, 1p, 13q, 16q, 17p and 17q in human breast cancers (Sato et al, 1990 (Sato et al, , 1991 Takita et al, 1992; Saito et al, 1993; Harada et al, 1994; Ito et al, 1995 ). It appears that a variety of tumour-suppressor genes may influence the development and progression of breast cancer.
LOH occurs frequently on 16q in hepatocellular carcinomas (HCCs) and prostate cancers as well as in breast cancers (Carter et al, 1990; Tsuda et al, 1990) . Tsuda and Hirohashi (1995) and Radford et al (1995) found evidence that the putative tumoursuppressor gene(s) on 16q may be involved in early stage breast carcinogenesis. To define more precisely the location(s) of such genes, we examined 210 primary breast cancers and constructed a detailed deletion map of chromosome 16q.
MATERIALS AND METHODS Samples and DNA preparation
DNAs were extracted from frozen tissue samples as described previously (Sato et al, 1990) . Tumours were classified by pathologists according to the histological primary tumour, regional lymph nodes and distant metastases (TNM) classification and the histological typing scheme of the Japanese Breast Cancer Society, into the following types: non-invasive tubular (la), invasive papillotubular (al), invasive solid tubular (a2), invasive scirrhous carcinoma (a3) and other specific types (b group). This classification is essentially the same as the World Health Organization scheme for typing breast tumours. Oestrogen receptor (ER) and progesterone receptor (PgR) were measured by radioreceptor assay in a strand dextrancoated charcoal (DCC) method, using [1251] oestradiol as labelled ligand on homogenates of individual fresh-frozen tissues (Otsuka Pharmaceutical Co.). All samples containing > 5fmol of ER or PgR mg-' protein were considered receptor positive.
LOH analysis
Fifteen polymorphic microsatellite markers (D16S401, D16S419, D16S408, D16S514, D16S512, D16S515, D16S518, D16S504, D16S507, D16S511, D16S402, D16S520, D16S498, D16S413, D16S303) were used in this study (Thompson et al, 1992; Gyapay et al, 1994; Kozman et al, 1995; Durocher et al, 1995 , Callen et al, 1995 . Each was amplified by the polymerase chain reaction (PCR) in 10-,ul volumes of mixture containing lx PCR buffer (30 mM Tris-HCl pH8.8, 50 mm potassium chloride, 2 mm magnesium chloride, 5 mm P-mercaptoethanol), 200 Cetus, Norwalk, CT, USA). Loading buffer (10 tl) was added to each reaction, and the samples were denatured. Auquots of 5 ,tl of each solution were electrophoresed in a 6% polyacrylamide gel containing 7.7 M formamide, for 4-5 h at 1500-2000 V. Gels were dried and exposed to Fuji X-ray film for 24-48 h. Signal intensities of the polymorphic alleles were quantified by a Hoefer GS-300 Thompson et al (1992) , Gyapay et al (1994) , Kozman et al (1995) , Durocher et al (1995) and Callen et al (1995) , and shows their frequencies of LOH in the breast tumours examined. LOH was observed most frequently at D16S518 (62%) at q22 and at D16S413 (65%) on q24.3. Among the 141 tumours that had lost an allele for at least one locus, 59 showed LOH at all loci tested, suggesting loss of the whole chromosomal arm; the other 82 showed a pattern of partial or interstitial deletion of 16q.
Representative autoradiograms of cases that revealed interstitial deletions of the 16q22 region are presented in Figure IA . Tumour 512 showed LOH at D16S512, whereas two flanking loci, D16S514 and D16S515, retained heterozygosity. Tumour 710 showed LOH for D16S515, but retained heterozygosity for D16S512 and D16S518. Figure l B shows representative autoradiograms of cases that exhibited interstitial or telomeric deletion of 16q24.3. Tumour 152 showed LOH at D16S520 but retained heterozygosity at D16S402 and S16S303. Tumour 166 showed LOH at D16S413 but retained D16S498.
Of the 82 tumours that showed partial or interstitial deletions of 16q, the 13 represented in Figure 2A as a deletion map showed deletions at or around 16q22. These cases were used to define a commonly deleted region. The (246 and 710) that retained heterozygosity at D16S512 while showing LOH at more distal loci. The distal limit was defined by D16S515; four tumours (252, 512, 788 and 794) retained heterozygosity with D16S515 while showing LOH at more proximal loci. Hence, the commonly deleted region was localized to a 3-cM interval flanked by D16S512 and D16S515. Figure 2B shows seven cases that exhibited deletions only at or around 16q24. This distal common region of deletion was confined to a 9.5-cM interval flanked by D16S498 and D16S303 at 16q24.3.
We also compared LOH on 16q with clinicopathological parameters including tumour size and infiltration, lymph node metastasis, ER status, PgR status and histopathological classification ( Table 2 ). The frequency of LOH was not significantly different from one clinicopathologically defined group to another, and LOH on 16q was not specifically associated with any of these parameters.
DISCUSSION
Loss of chromosome 16 is one of the most frequent cytogenetic abnormalities observed in primary breast cancers. We present here the results of high-resolution deletion mapping of 210 breast cancers using 15 microsatellite markers on 16q. We identified two target regions of common deletion on 16q in breast cancers. The more proximal of these regions was defined in a 3-cM interval between D16S512 and D16S515 at 16q22; the other was defined in a 9.5-cM interval between D16S498 and D16S303 at 16q24.3. Cleton-Jansen et al (1994) also described two commonly deleted regions in breast cancers, one between D16S398 and D16S301 and a more distal region between APRT and D16S303. APRT is located distal to D16S413 and proximal to D16S303. Although located close to one another, the more proximal of these regions did not correspond to the one we defined at 16q22 in the present study. A more detailed mapping study will be necessary to clarify a relationship between the results of the two studies.
LOH of 16q has been observed frequently in HCCs (Tsuda et al, 1990 ) and in prostate cancers as well (Carter et al, 1990) . The common region of deletion described in HCC was located within a 16-cM interval between HP and CTRB at q22. 1-q23.2. HP is located distal to D16S514. CTRB is located in an interval flanked by D16S515 and D16S402. The proximal target we defined in breast cancers falls within the same region.
Reduced expression or mutation in the E-cadherin gene on chromosome 16q22 has been described in a few cases of a rare type of human breast cancer, lobular carcinoma (Kanai et al, 1994; Berx et al, 1995) . The majority of the cancers analysed in the present study belongs to a more common type of carcinoma, ductal carcinoma. No mutation of the E-cadherin gene has been described in this type. Moreover, the E-cadherin gene was found to be more proximal to the commonly deleted region and was excluded from a list of candidate genes through our deletion mapping analysis.
The region deleted most frequently in breast cancers is at 16q24.3 (Cleton-Jansen et al, 1994; Tsuda et al, 1994; Skirnisdottir et al, 1995) . We also detected frequent LOH at this region in the study reported here: >60% at D16S520, D16S498 and D16S413. Together, the data suggest that a putative tumour-suppressor gene for breast cancer exists within a 9.5-cM interval at 16q24.3. Radford et al (1995) found frequent LOH on 16q and 17p in preinvasive ductal carcinomas in situ, and provided evidence that British Journal of Cancer (1997) loss of 16q is associated with breast tumorigenesis before progression to invasive cancer. In the present study, LOH on 16q was observed frequently in small tumours, tumours without lymph node metastasis and tumours of non-invasive histological type as well as in tumours of more advanced phenotype. Tsuda et al (1994) also observed frequent LOH on 16q in tumours of low or moderate histological grade of atypia as well as in those of a higher grade of atypia. All these data are consistent with the notion that LOH on 16q is an early event in breast carcinogenesis, and they suggest that inactivation of one or more tumour-suppressor genes on this chromosome is responsible. 
